USPTO Seeks Comments on Standard Trademark Board Paperwork
Published Date: 6/10/2026
Notice
Summary
The USPTO is asking for public feedback on continuing to collect info about Trademark Trial and Appeal Board (TTAB) actions, which affect businesses and individuals dealing with trademarks. This is a routine step to keep paperwork in check and won’t change fees or deadlines. You’ve got until August 10, 2026, to share your thoughts before the government gives the final thumbs-up.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 2 costs, 2 mixed.
Time and Labor Burden on Filers
The USPTO estimates 44,550 annual respondents and 76,000 annual responses for TTAB actions. The collection is estimated to require 1,016,891 total burden hours and an estimated hourly labor cost burden of $347,776,722 per year.
Filing Fees and Non-Hour Costs Remain
The notice lists existing TTAB filing fees and non-hour costs totaling an estimated $10,725,767 per year in filing fees and $767 in postage. Example fees include $600 per electronic Petition to Cancel, $600 per electronic Notice of Opposition, $200 per electronic Request for Extension in some cases, and $225 per electronic Ex Parte Appeal filing.
TTAB Information Collection Continued
The USPTO is asking to extend its existing information collection for Trademark Trial and Appeal Board (TTAB) actions (OMB Control No. 0651-0040). The agency seeks public comments by August 10, 2026, but this notice does not change existing fees or deadlines.
Electronic Filing Required (Mostly)
TTAB filings must be submitted electronically through the TTAB electronic filing system, though the USPTO allows paper submission by mail or hand delivery in certain circumstances.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17525, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Substantive Submissions Made During the Prosecution of the Trademark Application
The United States Patent and Trademark Office (hereafter "USPTO" or "Agency"), as required by the Paperwork Reduction Act of 1995, invites comments on the extension and revision of an existing information collection: 0651-0054 (Substantive Submissions Made During the Prosecution of the Trademark Application). The purpose of this notice is to allow 60 days for public comments preceding submission of the information collection to the Office of Management and Budget (OMB).
2026-17524, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Patent Trial and Appeal Board (PTAB) Appeals
The United States Patent and Trademark Office (hereafter "USPTO" or "Agency") will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The USPTO invites comments on the information collection renewal of 0651-0063, which helps the USPTO assess the impact of its information collection requirements and minimize the reporting burden to the public. Public comments were previously requested via the Federal Register on April 20, 2026, during a 60-day comment period (91 FR 20986). This notice allows for an additional 30 days for public comments.
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
Previous / Next Documents
Previous: 2026-11574, Tris (Hydroxymethyl) Aminomethane and Tris (Hydroxymethyl) Aminomethane Hydrochloride (“Tris and Tris HCl”) From China; Determinations
The U.S. government is investigating whether imports of Tris and Tris HCl from China are hurting American businesses by being sold unfairly cheap or with government help. If confirmed, this could lead to new rules or tariffs to protect U.S. industries. Companies and consumers should watch for updates later this year that might affect prices and trade.
Next: 2026-11578, Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.